Baseline erythrocyte sedimentation rate level predicts long-term inhibition of radiographic progression by tocilizumab: the KURAMA cohort
AbstractThe short-term effect of tocilizumab (TCZ) on the radiographic progression of rheumatoid arthritis has been reported; however, reports on its long-term effects are scarce. In this study, we aimed to evaluate its long-term effects on joint destruction in patients who had been treated with TCZ...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-04-01
|
| Series: | Immunological Medicine |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/25785826.2023.2170384 |
| _version_ | 1827946659371286528 |
|---|---|
| author | Ryu Watanabe Kosaku Murakami Toshimitsu Fujisaki Hiromu Ito Koichi Murata Wataru Yamamoto Takayuki Fujii Hideo Onizawa Akira Onishi Masao Tanaka Akio Morinobu Motomu Hashimoto |
| author_facet | Ryu Watanabe Kosaku Murakami Toshimitsu Fujisaki Hiromu Ito Koichi Murata Wataru Yamamoto Takayuki Fujii Hideo Onizawa Akira Onishi Masao Tanaka Akio Morinobu Motomu Hashimoto |
| author_sort | Ryu Watanabe |
| collection | DOAJ |
| description | AbstractThe short-term effect of tocilizumab (TCZ) on the radiographic progression of rheumatoid arthritis has been reported; however, reports on its long-term effects are scarce. In this study, we aimed to evaluate its long-term effects on joint destruction in patients who had been treated with TCZ for at least two years and for whom X-rays were available. Radiographic progression was evaluated with modified Total Sharp Score (mTSS), and structural remission was defined as the mean annual change in mTSS ≤0.5. Of the 59 patients included in this study (median age, 62 years; female, 81.4%), 34 patients (57.6%) achieved structural remission. Patients who achieved structural remission were relatively younger (59 years vs. 64 years, p = .06), had relatively higher proportion of anti-citrullinated protein antibody positivity (91.2% vs. 72.0%, p = .08), relatively lower C-reactive protein level (0.6 mg/dL vs. 2.2 mg/dL, p = .05), and significantly lower erythrocyte sedimentation rate (ESR) level (28.0 mm/h vs 65.5 mm/h, p = .003) than those who did not. Multivariate logistic regression analysis demonstrated that the baseline ESR level was significantly associated with structural remission (odds ratio, 0.98; 95% confidence interval: 0.96–0.99, p = .049). The baseline ESR level is a critical determinant of the long-term effect of TCZ on joint destruction. |
| first_indexed | 2024-03-13T11:03:42Z |
| format | Article |
| id | doaj.art-b4fb2b7851604d35a5fd1e1396aa87f0 |
| institution | Directory Open Access Journal |
| issn | 2578-5826 |
| language | English |
| last_indexed | 2024-03-13T11:03:42Z |
| publishDate | 2023-04-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Immunological Medicine |
| spelling | doaj.art-b4fb2b7851604d35a5fd1e1396aa87f02023-05-16T13:29:32ZengTaylor & Francis GroupImmunological Medicine2578-58262023-04-01462849210.1080/25785826.2023.2170384Baseline erythrocyte sedimentation rate level predicts long-term inhibition of radiographic progression by tocilizumab: the KURAMA cohortRyu Watanabe0Kosaku Murakami1Toshimitsu Fujisaki2Hiromu Ito3Koichi Murata4Wataru Yamamoto5Takayuki Fujii6Hideo Onizawa7Akira Onishi8Masao Tanaka9Akio Morinobu10Motomu Hashimoto11Department of Clinical Immunology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, JapanDivision of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, JapanR&D Center, Digital Solutions Business Unit, CAC Corporation, Tokyo, JapanDepartment of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, JapanDepartment of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, JapanDepartment of Health Information Management, Kurashiki Sweet Hospital, Kurashiki, JapanDepartment of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, JapanDepartment of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, JapanDepartment of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, JapanDepartment of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, JapanDepartment of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, JapanDepartment of Clinical Immunology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, JapanAbstractThe short-term effect of tocilizumab (TCZ) on the radiographic progression of rheumatoid arthritis has been reported; however, reports on its long-term effects are scarce. In this study, we aimed to evaluate its long-term effects on joint destruction in patients who had been treated with TCZ for at least two years and for whom X-rays were available. Radiographic progression was evaluated with modified Total Sharp Score (mTSS), and structural remission was defined as the mean annual change in mTSS ≤0.5. Of the 59 patients included in this study (median age, 62 years; female, 81.4%), 34 patients (57.6%) achieved structural remission. Patients who achieved structural remission were relatively younger (59 years vs. 64 years, p = .06), had relatively higher proportion of anti-citrullinated protein antibody positivity (91.2% vs. 72.0%, p = .08), relatively lower C-reactive protein level (0.6 mg/dL vs. 2.2 mg/dL, p = .05), and significantly lower erythrocyte sedimentation rate (ESR) level (28.0 mm/h vs 65.5 mm/h, p = .003) than those who did not. Multivariate logistic regression analysis demonstrated that the baseline ESR level was significantly associated with structural remission (odds ratio, 0.98; 95% confidence interval: 0.96–0.99, p = .049). The baseline ESR level is a critical determinant of the long-term effect of TCZ on joint destruction.https://www.tandfonline.com/doi/10.1080/25785826.2023.2170384Erythrocyte sedimentation ratemodified Total Sharp Scoreradiographic progressionrheumatoid arthritistocilizumab |
| spellingShingle | Ryu Watanabe Kosaku Murakami Toshimitsu Fujisaki Hiromu Ito Koichi Murata Wataru Yamamoto Takayuki Fujii Hideo Onizawa Akira Onishi Masao Tanaka Akio Morinobu Motomu Hashimoto Baseline erythrocyte sedimentation rate level predicts long-term inhibition of radiographic progression by tocilizumab: the KURAMA cohort Immunological Medicine Erythrocyte sedimentation rate modified Total Sharp Score radiographic progression rheumatoid arthritis tocilizumab |
| title | Baseline erythrocyte sedimentation rate level predicts long-term inhibition of radiographic progression by tocilizumab: the KURAMA cohort |
| title_full | Baseline erythrocyte sedimentation rate level predicts long-term inhibition of radiographic progression by tocilizumab: the KURAMA cohort |
| title_fullStr | Baseline erythrocyte sedimentation rate level predicts long-term inhibition of radiographic progression by tocilizumab: the KURAMA cohort |
| title_full_unstemmed | Baseline erythrocyte sedimentation rate level predicts long-term inhibition of radiographic progression by tocilizumab: the KURAMA cohort |
| title_short | Baseline erythrocyte sedimentation rate level predicts long-term inhibition of radiographic progression by tocilizumab: the KURAMA cohort |
| title_sort | baseline erythrocyte sedimentation rate level predicts long term inhibition of radiographic progression by tocilizumab the kurama cohort |
| topic | Erythrocyte sedimentation rate modified Total Sharp Score radiographic progression rheumatoid arthritis tocilizumab |
| url | https://www.tandfonline.com/doi/10.1080/25785826.2023.2170384 |
| work_keys_str_mv | AT ryuwatanabe baselineerythrocytesedimentationratelevelpredictslongterminhibitionofradiographicprogressionbytocilizumabthekuramacohort AT kosakumurakami baselineerythrocytesedimentationratelevelpredictslongterminhibitionofradiographicprogressionbytocilizumabthekuramacohort AT toshimitsufujisaki baselineerythrocytesedimentationratelevelpredictslongterminhibitionofradiographicprogressionbytocilizumabthekuramacohort AT hiromuito baselineerythrocytesedimentationratelevelpredictslongterminhibitionofradiographicprogressionbytocilizumabthekuramacohort AT koichimurata baselineerythrocytesedimentationratelevelpredictslongterminhibitionofradiographicprogressionbytocilizumabthekuramacohort AT wataruyamamoto baselineerythrocytesedimentationratelevelpredictslongterminhibitionofradiographicprogressionbytocilizumabthekuramacohort AT takayukifujii baselineerythrocytesedimentationratelevelpredictslongterminhibitionofradiographicprogressionbytocilizumabthekuramacohort AT hideoonizawa baselineerythrocytesedimentationratelevelpredictslongterminhibitionofradiographicprogressionbytocilizumabthekuramacohort AT akiraonishi baselineerythrocytesedimentationratelevelpredictslongterminhibitionofradiographicprogressionbytocilizumabthekuramacohort AT masaotanaka baselineerythrocytesedimentationratelevelpredictslongterminhibitionofradiographicprogressionbytocilizumabthekuramacohort AT akiomorinobu baselineerythrocytesedimentationratelevelpredictslongterminhibitionofradiographicprogressionbytocilizumabthekuramacohort AT motomuhashimoto baselineerythrocytesedimentationratelevelpredictslongterminhibitionofradiographicprogressionbytocilizumabthekuramacohort |